Jeannine Brant on the Benefits of Patient-Reported Outcomes

Video
Conferences|ONS Annual Congress

Jeannine Brant, PhD, Billings Clinic, discusses the benefits of patient-reported outcomes in cancer care.

Jeannine Brant, PhD, Billings Clinic, discusses the benefits of patient-reported outcomes in cancer care.

Here, she mentions an example of a patient who was a rectal cancer survivor and an avid runner. The patient had to quit the sport because whenever she would run, she would get severe diarrhea. However, she never discussed this with her nurses and doctor until she used Carevive, a system that lets patients log and rate any side effects that occur so that they can be brought up at medical appointments and addressed.

Related Videos
Alyssa Ridad
Yelena Shames
Johanna Garibaldi
Elizabeth Cullen
Shivani Gopalsami
Seth Eisenberg
Pattie Jakel
Kellie Zeichner
Brenda Martone
Related Content
Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit

Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit

April 12th 2024
Article

Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.

The Vitals

Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

June 15th 2023
Podcast

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Lenvatinib Plus Pembrolizumab Improves Survival in Advanced/Recurrent Endometrial Cancer

Lenvatinib Plus Pembrolizumab Improves Survival in Advanced/Recurrent Endometrial Cancer

April 1st 2024
Article

Criteria for progression-free and overall survival endpoints in patients with endometrial cancer with mismatch repair proficient disease were not met.

The Vitals

Seth Eisenberg Discusses New Methods of Reducing Hazardous Drug–Contaminated Toilet Aerosols in Hospital Setting

June 1st 2023
Podcast

Seth Eisenberg, ASN, RN, OCN, BMTCN, emphasizes the importance of reducing nurse exposure to hazardous drugs—and ongoing research efforts to improve nursing safety.

Pembrolizumab Plus Chemo Provides Overall Survival Benefit in Endometrial Cancer

Pembrolizumab Plus Chemo Provides Overall Survival Benefit in Endometrial Cancer

March 26th 2024
Article

Patients across endometrial cancer subgroups derived a favorable survival benefit with pembrolizumab plus chemotherapy in the KEYNOTE-868 trial.

Dostarlimab Plus Chemo Demonstrates 31% OS Improvement in Advanced Endometrial Cancer

Dostarlimab Plus Chemo Demonstrates 31% OS Improvement in Advanced Endometrial Cancer

March 25th 2024
Article

Patients with microsatellite instability high primary advanced or recurrent endometrial cancer derived a significant survival benefit when treated with dostarlimab plus chemotherapy.

© 2024 MJH Life Sciences

All rights reserved.